Samsung Bioepis Posts Double-Digit Growth with Q1 Sales of 454.9 Billion Won and Operating Profit of 144 Billion Won

Global Biosimilar Sales Maintain Strong Momentum
Accelerating Launch of New Biosimilars and Proprietary Drug Development

Samsung Bioepis posted sales of 454.9 billion won and operating profit of 144 billion won in the first quarter of this year, driven by the expansion of global biosimilar sales. These figures represent year-on-year increases of 14% and 13% respectively.

Samsung Bioepis Headquarters. Samsung Bioepis

According to the earnings announcement by Samsung Epis Holdings on April 23, Samsung Bioepis's first-quarter sales increased by 54.3 billion won and operating profit rose by 16.1 billion won compared to the same period last year. This performance exceeds the annual sales growth guidance (over 10%) presented at the beginning of the year. A Samsung Bioepis official explained, "We continued our growth momentum through increased profits from global biosimilar product sales and the expansion of our new portfolio."

The company is diversifying its product and sales strategies with a dual focus on Europe and the United States. In Europe, it currently sells four products directly, including the Enbrel biosimilar 'SB4', with sales of existing product lines remaining steady. For the Eylea biosimilar 'SB15', preparations are underway to launch in Europe in April this year and in the United States in January next year.

In the United States, the Prolia biosimilar 'SB16' has emerged as a new growth driver. This product entered the market in January after Samsung Bioepis signed a private label supply agreement with CVS Caremark, one of the top three PBMs in the U.S. Since then, it has been added to the CVS Caremark preferred drug list, and the company is focusing on securing market share and expanding sales.

The partnership strategy has also accelerated. In March, Samsung Bioepis signed an early-partnership agreement with Sandoz for the research, development, and commercialization of the Entyvio biosimilar 'SB36', targeting a preclinical pipeline. The intention is to increase the chances of commercialization success by integrating the expertise of both companies from the early development stage.

The company is also accelerating new drug development, with a particular focus on the antibody-drug conjugate (ADC) segment, which is considered a next-generation cancer therapy. Its first ADC drug candidate, 'SBE303', entered global Phase 1 clinical trials in March, and on April 20, preclinical data on efficacy and safety improvements were released at the American Association for Cancer Research (AACR) 2026. The second candidate, 'SBE313', is undergoing preclinical development in collaboration with Frontline in China.

The holding company, Samsung Epis Holdings, also showed improved performance. On a consolidated basis, it achieved first-quarter sales of 453.9 billion won and operating profit of 90.5 billion won, returning to operating profit in the first quarter since its establishment. This marks a turnaround from operating losses of 63.6 billion won recorded in November and December last year. Samsung Epis Holdings explained that this was due to the impact of non-cash accounting adjustments such as amortization of PPA development costs.

This content was produced with the assistance of AI translation services.